Business Context and Reporting Period
Company: GSK Plc
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: Three months ended 31 March 2017 (Q1 2017)
Issuance Date: 26 April 2017
GSK reported a positive start to the year with sales growth across all three business segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The results reflect strong commercial execution, improved operating margins, and the benefits of restructuring programs.
Key Financial Metrics
| Metric | Q1 2017 | Q1 2016 | Growth (AER) | Growth (CER) |
|---|---|---|---|---|
| Turnover | £7,384 million | £6,229 million | +19% | +5% |
| Total Operating Profit | £1,718 million | £723 million | >100% | 100% |
| Adjusted Operating Profit | £1,979 million | £1,524 million | +30% | +9% |
| Total EPS | 21.4p | 5.8p | >100% | >100% |
| Adjusted EPS | 25.0p | 19.1p | +31% | +9% |
| Net Cash from Operations | £1,144 million | £503 million | >100% | N/A |
| Free Cash Flow | £650 million | (£240 million) | >100% | N/A |
| Net Debt | £13,743 million | £12,495 million | N/A | N/A |
Note: AER = Actual Exchange Rates; CER = Constant Exchange Rates.
Segment Performance
- Pharmaceuticals: Turnover £4,189 million (+17% AER, +4% CER). Adjusted operating margin 34.4%.
- Vaccines: Turnover £1,152 million (+31% AER, +16% CER). Adjusted operating margin 29.6%.
- Consumer Healthcare: Turnover £2,043 million (+16% AER, +2% CER). Adjusted operating margin 17.2%.
Material Changes vs. Prior Period
- Profitability Surge: Total operating profit more than doubled compared to Q1 2016, driven by a £245 million gain on the disposal of the anaesthesia business to Aspen and reduced transaction-related accounting charges.
- Product Mix: New product sales (Pharmaceuticals and Vaccines) reached £1.4 billion, up 72% AER. Key drivers included Triumeq, Tivicay, and the Ellipta respiratory portfolio.
- Divestments: The disposal of the anaesthesia business contributed significantly to operating income. The Nigeria beverages business disposal in the prior year impacted Consumer Healthcare comparisons.
- Cost Control: SG&A costs as a percentage of turnover decreased by 1.9 percentage points (AER) due to lower restructuring costs and tight cost control.
Guidance, Outlook, and Risks
Guidance and Outlook
- 2017 Adjusted EPS: Guidance maintained at 5-7% growth on a CER basis, assuming no generic entry for Advair in the US in 2017. If a generic enters mid-year, EPS is expected to be flat to slightly down.
- Dividends: Q1 2017 interim dividend declared at 19p per share. Full year 2017 dividend expected to be 80p.
- New Product Targets: Sales of new Pharmaceutical and Vaccine products are on track to reach £6 billion (CER) annually in 2018.
Risks and Contingencies
- Advair Generic Competition: The primary risk to 2017 guidance is the potential introduction of a generic version of Advair in the US market.
- Legal Proceedings: Ongoing litigation regarding product liability, intellectual property, and tax matters. A provision of £0.4 billion exists for legal disputes. Teva Pharmaceuticals challenged patents covering Flovent HFA.
- Contingent Consideration: Significant liabilities exist related to the ViiV Healthcare and Novartis Vaccines acquisitions, subject to re-measurement based on product performance and exchange rates.
Investor Verification Checklist
- Advair Patent Status: Verify the timeline and likelihood of generic entry for Advair in the US, as this is the critical variable for 2017 EPS guidance.
- Contingent Consideration Liabilities: Review the balance sheet impact of re-measurements related to ViiV Healthcare (Shionogi/Pfizer) and Novartis Vaccines, which fluctuate with product sales and exchange rates.
- Free Cash Flow Definition: Note the change in Free Cash Flow definition from Q1 2017, which now includes contingent consideration payments.
- Legal Provisions: Monitor developments in the Teva Flovent patent challenge and other significant litigation mentioned in the "Legal Matters" section.
- Divestment Proceeds: Confirm the utilization of the £229 million disposal proceeds from the anaesthesia business.